GSK Marks Second Lung Cancer Drug Approval This Year

Source: Benzinga ·

GSK Marks Second Lung Cancer Drug Approval This Year

On Tuesday, the Food and Drug Administration granted accelerated approval to GSK Plc.’s (NYSE:GSK) Nelkarmi (neladalkib) for locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The milestone marks the second lung cancer app

Read the full story at Benzinga

Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.

More from the world desk